Literature DB >> 2807010

Clear cell carcinoma of the ovary: a study of 59 cases.

M A Crozier1, L J Copeland, E G Silva, D M Gershenson, C A Stringer.   

Abstract

Clear cell carcinoma of the ovary accounts for 2 to 3% of all epithelial ovarian neoplasms. Patient profiles, pathological characteristics, and results of treatment are reviewed for 59 patients. The median age was 51. Disease extent at diagnosis was as follows: stage I, 18 patients (31%); stage II, 20 patients (34%); stage III, 15 patients (25%); stage IV, 3 patients (5%); and unknown stage, 3 patients (5%). Endometriosis was identified in 13 patients (22%). Hysterectomy and bilateral salpingo-oophorectomy were performed in 47 patients (80%), unilateral salpingo-oophorectomy in 8 patients (14%), and bilateral salpingo-oophorectomy in 4 patients (7%). Radiotherapy was given to 15 patients (25%), and chemotherapy was given to 42 patients (71%). The overall 2- and 5-year survival rates were 49 and 43%. The median survival was 26 months. Patients with tumors with fewer than 10 mitoses per 10 high-power fields and less than 50% solid areas had significantly longer disease-free intervals. Clear cell tumors are usually diagnosed at an earlier disease stage than the other epithelial ovarian cancers; stage for stage, however, the prognoses are similar.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807010     DOI: 10.1016/0090-8258(89)90043-7

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  Clear Cell Adenocarcinofibroma Ovary - A Rare Histopathological Variant with Unusual Presentation.

Authors:  Manjit Kaur; Navtej Singh; Amrit Pal Singh Rana
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Ovarian clear cell adenocarcinoma: a continuing enigma.

Authors:  David S P Tan; Stan Kaye
Journal:  J Clin Pathol       Date:  2006-10-03       Impact factor: 3.411

3.  Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.

Authors:  Emily N Prendergast; Marie Holzapfel; Jennifer J Mueller; Mario M Leitao; Camille C Gunderson; Kathleen N Moore; Britt K Erickson; Charles A Leath; Elena S Diaz Moore; Joshua G Cohen; Christine S Walsh
Journal:  Gynecol Oncol       Date:  2016-12-12       Impact factor: 5.482

Review 4.  Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.

Authors:  Daichi Maeda; Ie-Ming Shih
Journal:  Adv Anat Pathol       Date:  2013-01       Impact factor: 3.875

5.  HNF-1β in ovarian carcinomas with serous and clear cell change.

Authors:  Deborah DeLair; Guangming Han; Julie A Irving; Samuel Leung; Carol A Ewanowich; Teri A Longacre; Cyril B Gilks; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2013-11       Impact factor: 2.762

6.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

7.  Gene expression patterns in ovarian carcinomas.

Authors:  Marci E Schaner; Douglas T Ross; Giuseppe Ciaravino; Therese Sorlie; Olga Troyanskaya; Maximilian Diehn; Yan C Wang; George E Duran; Thomas L Sikic; Sandra Caldeira; Hanne Skomedal; I-Ping Tu; Tina Hernandez-Boussard; Steven W Johnson; Peter J O'Dwyer; Michael J Fero; Gunnar B Kristensen; Anne-Lise Borresen-Dale; Trevor Hastie; Robert Tibshirani; Matt van de Rijn; Nelson N Teng; Teri A Longacre; David Botstein; Patrick O Brown; Branimir I Sikic
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

8.  Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.

Authors:  Catherine A Shu; Qin Zhou; Anjali R Jotwani; Alexia Iasonos; Mario M Leitao; Jason A Konner; Carol A Aghajanian
Journal:  Gynecol Oncol       Date:  2015-09-25       Impact factor: 5.482

9.  Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.

Authors:  Sunyoung Lee; Elizabeth I O Garner; William R Welch; Ross S Berkowitz; Samuel C Mok
Journal:  Gynecol Oncol       Date:  2007-05-25       Impact factor: 5.482

10.  Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance.

Authors:  Oluwole Fadare; Sharon X Liang; Marta A Crispens; Howard W Jones; Dineo Khabele; Katja Gwin; Wenxin Zheng; Khaled Mohammed; Vinita Parkash; Jonathan L Hecht; Mohamed M Desouki
Journal:  Hum Pathol       Date:  2013-03-01       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.